HighLife
HighLife develops a trans-septal mitral valve replacement (TSMVR) system designed to treat patients with moderate to severe mitral regurgitation. The technology provides a transcatheter alternative to traditional surgery for the most common heart valve condition. The system has received CE Mark approval and is undergoing investigational use in the United States.
Visit websiteParis, France
Healthtech
Medical Devices
Cardiology
Funding summary
- Total raised
- €44.3M
- Funding rounds
- 2
Investors in HighLife
Investors on record for HighLife. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like HighLife?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors